Skip to main content
SpringerLink
Log in

Sentinel Lymph Node Metastases Detected by Immunohistochemistry Only Do Not Mandate Complete Axillary Lymph Node Dissection in Breast Cancer

  • Original Article
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: The significance of breast cancer sentinel lymph node (SLN) metastases detected only by immunohistochemistry staining (IHC) remains poorly understood. This study attempted to quantify the risk of non-SLN metastases.

Methods: A prospectively collected database of 750 consecutive SLN biopsy procedures in breast cancer patients was reviewed. Medical records were reviewed to supplement the database.

Results: SLNs were identified in 738 (98.4%) of these procedures in 723 patients. Of these, 151 patients (20.5%) had metastases detected by hematoxylin and eosin staining (H&E), and 33 (4.6%) of the 718 with known IHC staining results had metastases detected by IHC only. Twenty-eight (84.8%) of 33 patients with IHC-detected metastases underwent complete axillary lymph node dissection (CALND). The median primary tumor size was 2.0 cm among those undergoing CALND and 0.9 cm among the five patients treated without CALND (P = .10). Two of the 28 patients (7.1%) had additional metastases detected with CALND. These patients had a T3 or T4 invasive lobular primary tumor. Of 24 patients with T1 or T2 primary tumors and IHC-detected metastases who underwent CALND, none had additional metastases detected. Median follow-up was 14.5 months. All patients with IHC-detected SLN metastases were treated with adjuvant systemic therapy. None of the five patients with IHC-detected metastases not undergoing CALND has subsequently manifested clinical axillary disease.

Conclusions: CALND could have been or was safely omitted in 29 of 29 patients with T1 or T2 primary tumors and metastases detected by IHC. Such patients should be counseled about this low risk before CALND is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818–22.

    Article  PubMed  CAS  Google Scholar 

  2. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15:2345–50.

    PubMed  CAS  Google Scholar 

  3. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181–7.

    Article  PubMed  CAS  Google Scholar 

  4. Schreiber RH, Pendas S, Ku NN, et al. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. Ann Surg Oncol 1998; 6:95–101.

    Article  Google Scholar 

  5. Czerniecki BJ, Scheff AM, Callans LS, et al. Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer 1999; 85:1098–103.

    Article  PubMed  CAS  Google Scholar 

  6. Teng S, Dupont E, McCann C, et al. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer? Am Surg 2000; 66:574–8.

    PubMed  CAS  Google Scholar 

  7. Dowlatshahi K, Fan M, Bloom KJ, Spitz DJ, Patel S, Snider HC Jr. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: A preliminary study. Cancer 1999; 86:990–6.

    Article  PubMed  CAS  Google Scholar 

  8. Hammond ME, Fitzgibbons PL, Compton CC, et al. Cancer Committee and Conference Participants. College of American Pathologists Conference XXXV. Solid tumor prognostic factors: Which, how and so what? Summary document and recommendations for implementation. Arch Path Lab Med 2000; 124:958–65.

    PubMed  CAS  Google Scholar 

  9. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast. Breast J 2002; 8:126–38.

    Article  Google Scholar 

  10. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999; 229:536–41.

    Article  PubMed  CAS  Google Scholar 

  11. Wong SL, Chao C, Edwards MJ, Simpson D, McMasters KM, University of Louisville Breast Cancer Study Group. The use of cytokeratin staining in sentinel lymph node biopsy for breast cancer. Am J Surg 2001; 182:330–4.

    Article  PubMed  CAS  Google Scholar 

  12. den Bakker MA, van Weeszenberg A, de Kanter AY, et al. Non-sentinel lymph node involvement in patients with breast cancer and sentinel node micrometastasis: too early to abandon axillary clearance. J Clin Path 2002; 55:932–5.

    Article  PubMed  CAS  Google Scholar 

  13. Jakub JW, Diaz NM, Ebert MD, et al. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am J Surg 2002; 184:302–6.

    Article  PubMed  Google Scholar 

  14. Hwang RF, Krishnamurthy S, Hunt KK, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003; 10:248–54.

    Article  PubMed  Google Scholar 

  15. Blanchard DK, Donohue JH, Reynolds C, Grant CS. Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 2003; 138:482–7.

    Article  PubMed  Google Scholar 

  16. Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000; 89:574–81.

    Article  PubMed  CAS  Google Scholar 

  17. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001; 67:513–9.

    PubMed  CAS  Google Scholar 

  18. Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol 2000; 7:636–42.

    Article  PubMed  CAS  Google Scholar 

  19. Silverstein MJ. Van Nuys experience by treatment. In: Silverstein MJ, ed. Ductal Carcinoma In Situ of the Breast. Baltimore: Williams & Wilkens, 1997:449.

    Google Scholar 

  20. Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003 Nov 15; 98(10):2105–13.

    Article  PubMed  Google Scholar 

  21. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233–41.

    Article  PubMed  Google Scholar 

  22. Early Breast Cancer Trialists’ Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 333:1444–55.

  23. Turner RR, Hansen NM, Stern SL, Giuliano AE. Intraoperative examination of the sentinel lymph node for breast carcinoma staging. Am J Clin Path 1999; 112:627–34.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Surgical Oncology, Department of Surgery, Mayo Clinic, Scottsdale, Arizona

    Richard J. Gray MD & Barbara A. Pockaj MD

  2. Section of Surgical Oncology, Department of Pathology, Mayo Clinic, Scottsdale, Arizona

    Christopher R. Conley MD

  3. CB Surgery, Mayo Clinic, Scottsdale, AZ, 85259

    Richard J. Gray MD

Authors
  1. Richard J. Gray MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara A. Pockaj MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christopher R. Conley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard J. Gray MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gray, R.J., Pockaj, B.A. & Conley, C.R. Sentinel Lymph Node Metastases Detected by Immunohistochemistry Only Do Not Mandate Complete Axillary Lymph Node Dissection in Breast Cancer. Ann Surg Oncol 11, 1056–1060 (2004). https://doi.org/10.1245/ASO.2004.03.037

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.03.037

Key Words

Search

Navigation